Rockwell Automation vs Revvity Inc — how do they compare? Rockwell Automation trades at $433.08 (market cap $48.21B), while Revvity Inc trades at $154.78 (market cap $16.98B). The key difference: Rockwell Automation is far larger — about 2.8× Revvity Inc's market cap, and Rockwell Automation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and Revvity Inc for 12 Days on average.
| ROK | RVTY | |
|---|---|---|
Market Cap | $48.21B | $16.98B |
Volume | 953,342 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $495.08 | $157.36 |
52-Week Low | $333.75 | $82.26 |
Typical Hold Time | 74 Days | 12 Days |
Enterprise Value | $51.34B | $19.30B |
Dividend Yield | 1.27% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $432.61, down 2.1% on the day, with a bearish technical signal. The stock shows strong profitability with a 13.38% net income margin and 34.47% ROE, but trades at elevated valuation multiples including a P/E of 40.65. Recent earnings have consistently beaten estimates, and the company maintains a solid cash flow profile. Positive news highlights its leadership in industrial automation and digital transformation initiatives.
The outlook is mixed: analyst consensus is a Buy with a $489.89 price target, implying potential upside, but high valuation and near-term technical weakness pose risks. Key catalysts include continued execution on automation demand trends, while risks involve macroeconomic sensitivity and competitive pressures.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →